Intratumoral immunotherapy: using the tumor as the remedy
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx683
Abstract: Immune checkpoint-targeted monoclonal antibodies directed at Programmed Death Receptor 1 (PD-1), Programmed Death Ligand 1 (PD-L1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) are currently revolutionizing the prognosis of many cancers. By blocking co-inhibitory receptors… read more here.
Keywords: cancer immunity; cancer; intratumoral immunotherapy; immunotherapy using ... See more keywords
Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer research"
DOI: 10.1158/0008-5472.can-21-1382
Abstract: The combination of the synthetic TLR9 ligand CpG and agnostic OX40 antibody can trigger systemic anti-tumor immune responses upon co-injection into the tumor microenvironment, eradicating simultaneous untreated sites of metastatic disease. Here we explore the… read more here.
Keywords: immunotherapy; intratumoral immunotherapy; cancer; ox40 antibody ... See more keywords
Abstract 711: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-711
Abstract: Despite the recent breakthrough of checkpoint blockade antibodies targeting T cells to combat cancer, it has become apparent that the majority of patients are not fully responsive. Engaging innate immune cells is a promising way… read more here.
Keywords: tlr7; agonist; intratumoral immunotherapy; cancer ... See more keywords
Intratumoral Immunotherapy and Tumor Ablation: A Local Approach with Broad Potential
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14071754
Abstract: Simple Summary The goal of immuno-oncology is to potentiate a durable antitumor immune response. The immunosuppressive tumor microenvironment (TME) presents a substantial challenge to current systemic therapies due in part to a lack of available… read more here.
Keywords: immunotherapy tumor; tumor ablation; approach; tumor ... See more keywords